Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

References

• Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001;104:517-29
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
   PubMed Web of Science ®Google Scholar
• Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999–2002, the National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-7
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:173-5
   PubMed Web of Science ®Google Scholar
• Berger J, Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996;137:4189-95
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206
   PubMed Web of Science ®Google Scholar
• Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477-85
   PubMed Web of Science ®Google Scholar
• Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297-300
   PubMed Web of Science ®Google Scholar
• Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of multiple oral doses of the dipeptidyl peptidase-4 inhibitor alogliptin benzoate in patients with type 2 diabetes. Clin Ther 2008;30:499-512
   PubMed Web of Science ®Google Scholar
• Moritoh Y, Takeuchi K, Kataoka O, et al. Pharmacological effects of combination treatment with alogliptin, a novel, highly selective dipeptidyl peptidase-IV inhibitor, and pioglitazone on glycemic control in ob/ob mice. Eur J Pharmacol 2009;602:448-54
   PubMed Web of Science ®Google Scholar
• Karim A, Fleck P, Joseph M, et al. No pharmacokinetic interaction between alogliptin benzoate (SYR-322) and pioglitazone hydrochloride [abstract]. Diabetes 2007;56:A536
   Google Scholar
• Fleck P, Christopher R, Covington P, et al. Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with type 2 diabetes [abstract]. Diabetes 2008;57:A143
   Web of Science ®Google Scholar
• Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brazg R, Andryuk PJ, et al.; and Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT, Dodis R, Viscoli CM, et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006;29:2137-9
   PubMed Web of Science ®Google Scholar
• European public assessment report for Galvus – scientific discussion. European Medicines Agency. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf [Last accessed 28 July 2008]
   Google Scholar
• Pratley R, Kipnes M, Fleck P, et al.; on behalf of the Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167-76
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Fleck PR, Wilson CA, et al.; on behalf of the Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-17
   PubMed Web of Science ®Google Scholar